Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the Use of Tumor Bank DNA to Validate Genetic Factors Impacting Opioid Response in Patients with Advanced Cancer.

Current oncology (Toronto, Ont.) - 17 Jun 2026

Watt Christine L, Lelievre Rebecca, Parsons Gaelle Chopin Stukart, Vergette Caroline, Chirip Venus, Polskaia Nadia, Lapenskie Julie, Lo Bryan, Campbell Pearl, Bankapur Asma, Palidwor Gareth, Downar James

Abstract excerpt

Opioids are first-line therapy for cancer pain, yet up to 30% of patients fail to achieve adequate control at standard doses. Opioid response is partly genetically mediated, and understanding these factors may improve symptom management. This project aimed to assess the feasibility of using tumor bank DNA for pharmacogenetic analyses and to validate previously identified genetic variants associated with opioid...

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
Analgesics, Opioid
DNA, Neoplasm
GCH1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 42346263
DOI: 10.3390/curroncol33060363
PMCID: PMC13298010

Genes

COMT
GCH1
NFKBIA
OPRM1
RHBDF2
TAOK3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the Use of Tumor Bank DNA to Validate Genetic Factors Impacting Opioid Response in Patients with Advanced Cancer.PMID 42346263Read ↗

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.Semantic proximity Read ↗

Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients.Semantic proximity Read ↗

Genetic Factors Associated With Pain Severity, Daily Opioid Dose Requirement, and Pain Response Among Advanced Cancer Patients Receiving Supportive Care.Semantic proximity Read ↗

Genetics and Opioids: Towards More Appropriate Prescription in Cancer PainSemantic proximity Read ↗

Multiple Loci modulate opioid therapy response for cancer pain.Semantic proximity Read ↗

Role of genetic polymorphisms on opioid safety and efficacy in cancer pain: A systematic review and meta-analysis.Semantic proximity Read ↗

Multi-variant Genetic Panel for Genetic Risk of Opioid Addiction.Semantic proximity Read ↗

Genetic Predictors of the Clinical Response to Opioid AnalgesicsSemantic proximity Read ↗

A genome-wide association study of European advanced cancer patients treated with opioids identifies regulatory variants on chromosome 20 associated with pain intensity.Semantic proximity Read ↗

Genetic associations of persistent opioid use after surgery: a hypothesis-driven analysis of high-value genetic variants in the Michigan Genomics Initiative datasetSemantic proximity Read ↗

Evidence Regarding Pharmacogenetics in Pain Management and Cancer.Semantic proximity Read ↗

Candidate Genes from an FDA-Approved Algorithm Fail to Predict Opioid Use Disorder Risk in Over 450,000 VeteransSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.